• Product
• Series of non-face-to-face medical care platforms close down
• by Jung, Sae-Im Jun 16, 2023 05:55am

• Company
• Ultomiris under review as myasthenia gravis Tx in Korea
• by Eo, Yun-Ho Jun 16, 2023 05:54am

• Opinion
• [Reporter's view] Homework left by ASCO 2023’ hot topic
• by Jung, Sae-Im Jun 16, 2023 05:53am

• Policy
• Why Vyndamax and Tabrecta’s reimb were unable to pass DREC
• by Lee, Tak-Sun Jun 15, 2023 05:38am

• Company
• Development of Recomid generics fierce despite reeval issue
• by Kim, Jin-Gu Jun 15, 2023 05:38am

• Company
• Samsung Bioepis emphasized the role of a similar
• by Hwang, byoung-woo Jun 14, 2023 05:38am

• Company
• The efficient use of CDK 4/6 needs to be discussed
• by Jun 14, 2023 05:38am

• Company
• Hanmi to examine the possibility of the Poseltinib effect
• by Chon, Seung-Hyun Jun 14, 2023 05:38am

• Company
• Hanmi's NASH drug candidate, designated as a fast track
• by Jun 14, 2023 05:38am

• Company
• Will a new treatment option be introduced for gastric cancer
• by Jung, Sae-Im Jun 14, 2023 05:38am